I see it regularly. A patient arrives having completed multiple courses of topical antibiotics, usually clindamycin. Their acne improved at first, then stabilised, then returned with equal or worse severity. Their GP told them the antibiotic had stopped working. They have concluded their skin does not respond to treatment. What they have is a skin microbiome significantly altered by repeated antibiotic exposure.
This is a pattern aesthetic practitioners need to recognise and respond to. It shapes the entire treatment approach.
What Happens to the Microbiome During Extended Antibiotic Use
The skin carries a diverse ecosystem of microorganisms. In a healthy state, Staphylococcus epidermidis produces short-chain fatty acids that suppress pathogenic Cutibacterium acnes strains. Corynebacterium species help maintain the slightly acidic pH that discourages pathogenic colonisation. Microbial diversity is itself protective.
Topical antibiotics used over extended periods reduce that diversity. Clindamycin and erythromycin are broad enough in their activity to suppress beneficial organisms alongside C. acnes. Over time, resistant strains of C. acnes populate the follicles, no longer responsive to the antibiotic that once controlled them. The diversity reduction also leaves fewer organisms producing the protective fatty acids that would otherwise help regulate the follicular environment.
NICE guideline NG198 on acne management explicitly recommends against antibiotic monotherapy and states that topical antibiotics should be combined with benzoyl peroxide to reduce resistance risk. The guidance advises against courses longer than three months. In practice, patients arriving at aesthetic practice have often been on antibiotics for considerably longer, without the benzoyl peroxide pairing.
What the Skin Typically Presents With
There are consistent features to look for. The inflammatory acne that initially responded has often returned to the same severity or worse. The distribution may have broadened. The treatment plateau is visible to the patient even when the resistance mechanism is not.
Frequently, the barrier has also been compromised. Patients who have not been using barrier-supportive products alongside antibiotic courses often present with increased sensitivity, reactivity, and signs of transepidermal water loss. Reduced microbial diversity and a disrupted barrier are two compounding problems that make the skin significantly less stable.
There is often a psychological dimension too. Patients who have tried treatment and experienced relapse carry expectations shaped by previous failure. Addressing this in the first consultation matters as much as the clinical plan itself.
What Aesthetic Practitioners Can and Cannot Do
The scope boundary is important here. If a patient has antibiotic-resistant acne that is not responding to topical treatment, they need a GP or dermatology referral. Isotretinoin remains the most effective treatment for persistent, antibiotic-resistant acne. That decision belongs with a prescriber who can assess suitability, monitor for side effects, and maintain the required pregnancy prevention programme where applicable.
What aesthetic practitioners can do is prepare the skin for successful management and address the elements that sit within scope.
Barrier restoration comes first. Ceramide-containing moisturisers, gentle pH-appropriate cleansing, and reduction of aggressive exfoliants give the skin the environment it needs to begin recovering microbial stability. Without addressing the barrier, any additional treatment sits on unstable ground.
Benzoyl peroxide, where appropriate, remains the most reliable topical option for managing C. acnes populations without driving resistance. No documented resistance to benzoyl peroxide exists after decades of clinical use. If a patient has not previously used benzoyl peroxide alongside their antibiotic, introducing it as part of a revised protocol is a clinically justified step.
Azelaic acid is useful in this context because it carries anti-inflammatory and antibacterial activity without the resistance concerns of topical antibiotics. NICE CKS lists it as a treatment option for inflammatory acne lesions. For patients with both active inflammation and post-inflammatory pigmentation, it addresses both.
Building the Post-Antibiotic Consultation Conversation
The first consultation is about the history. How long were the antibiotics used? Was benzoyl peroxide included? Has the skin ever fully cleared, or only partially improved? What does the current home skincare routine look like, and how many active ingredients does it include?
Simplification is usually the right clinical move before addition. A patient managing antibiotic-resistant acne with a seven-product routine including multiple acids is fighting against a destabilised microbiome with products that further destabilise it. The protocol needs to reflect the current skin state, not the idealised treatment target.
Set a realistic timeline. Post-antibiotic skin takes time to recover microbial balance. Improvement from benzoyl peroxide and barrier support is visible, but it takes longer than patients expect after being told antibiotics should show results in six to eight weeks. Twelve weeks is a more realistic assessment window.
Document clearly. If you are referring, a summary of the antibiotic history, timeline, products used, and the current clinical picture gives the GP or dermatologist a useful starting point and reduces the likelihood of the patient being cycled back to the same approach.
The microbiome is not a theoretical concept in this context. It is the practical explanation for why the previous treatment failed and the basis for what to do next.
If you see patients with a history of prolonged antibiotic courses that have not resolved their acne, Acne Decoded provides the clinical framework for assessment, treatment hierarchy, and the microbiome evidence that changes how practitioners approach these cases. It is built specifically for UK aesthetic practitioners and available at aestheticsunlocked.co.uk.